Alzheimer's disease (AD) is one of the top public health crises in the 21st century, especially in an aging society. Early diagnosis, prevention, and intervention can significantly reduce the risk of AD. Detection of multiple AD biomarkers in blood is an effective strategy and has drawn more and more attention in recent years. However, the concentration of AD biomarkers is very low, therefore, point-of-care testing (POCT) techniques are needed for sensitive detection. Herein, a lateral flow assay, based on Surface-enhanced Raman scattering nanotags (SERS-LFA), is proposed for the simultaneous quantification of multiple AD biomarkers including Amyloid-beta 42, Amyloid-beta 40, tau proteins, and neurofilament light chain. The limit of detection for four AD biomarkers is 138.1, 191.2, 257.1, and 309.1 fg mL⁻¹, respectively, which are two orders of magnitude lower than their concentrations in blood. Compared with the existing detection technology, SERS-LFA has the advantages of high specificity, high sensitivity, low cost, multiple detection, and rapid detection. Therefore, SERS-LFA has a broad application prospect in the early diagnosis and monitoring of AD in the future.

中文翻译：

---

SERS-LFA 对多种阿尔茨海默病生物标志物的超灵敏检测

阿尔茨海默病 (AD) 是 21 世纪最严重的公共卫生危机之一，尤其是在老龄化社会中。早期诊断、预防和干预可以显着降低 AD 的风险。检测血液中的多种 AD 生物标志物是一种有效的策略，近年来越来越受到关注。然而，AD 生物标志物的浓度非常低，因此需要即时检测 (POCT) 技术进行灵敏检测。本文提出了一种基于表面增强拉曼散射纳米标签 (SERS-LFA) 的横向流动测定法，用于同时定量多种 AD 生物标志物，包括 Amyloid-beta 42、Amyloid-beta 40、tau 蛋白和神经丝轻链。四种 AD 生物标志物的检测限为 138.1、191.2、257.1 和 309.1 fg mL ^-1，分别比它们在血液中的浓度低两个数量级。与现有的检测技术相比，SERS-LFA具有特异性高、灵敏度高、成本低、检测多、检测快等优点。因此，SERS-LFA在未来AD的早期诊断和监测中具有广阔的应用前景。